385 related articles for article (PubMed ID: 20015050)
1. Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA.
Owen KA; Qiu D; Alves J; Schumacher AM; Kilpatrick LM; Li J; Harris JL; Ellis V
Biochem J; 2010 Feb; 426(2):219-28. PubMed ID: 20015050
[TBL] [Abstract][Full Text] [Related]
2. Roles and regulation of membrane-associated serine proteases.
Qiu D; Owen K; Gray K; Bass R; Ellis V
Biochem Soc Trans; 2007 Jun; 35(Pt 3):583-7. PubMed ID: 17511657
[TBL] [Abstract][Full Text] [Related]
3. In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma.
Förbs D; Thiel S; Stella MC; Stürzebecher A; Schweinitz A; Steinmetzer T; Stürzebecher J; Uhland K
Int J Oncol; 2005 Oct; 27(4):1061-70. PubMed ID: 16142324
[TBL] [Abstract][Full Text] [Related]
4. TMPRSS13, a type II transmembrane serine protease, is inhibited by hepatocyte growth factor activator inhibitor type 1 and activates pro-hepatocyte growth factor.
Hashimoto T; Kato M; Shimomura T; Kitamura N
FEBS J; 2010 Dec; 277(23):4888-900. PubMed ID: 20977675
[TBL] [Abstract][Full Text] [Related]
5. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
Vines DJ; Lee SW; Dichek DA; Ellis V
J Pept Sci; 2000 Sep; 6(9):432-9. PubMed ID: 11016879
[TBL] [Abstract][Full Text] [Related]
6. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.
Webb CP; Hose CD; Koochekpour S; Jeffers M; Oskarsson M; Sausville E; Monks A; Vande Woude GF
Cancer Res; 2000 Jan; 60(2):342-9. PubMed ID: 10667586
[TBL] [Abstract][Full Text] [Related]
7. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
[TBL] [Abstract][Full Text] [Related]
8. Proteolytic processing of the serine protease matriptase-2: identification of the cleavage sites required for its autocatalytic release from the cell surface.
Stirnberg M; Maurer E; Horstmeyer A; Kolp S; Frank S; Bald T; Arenz K; Janzer A; Prager K; Wunderlich P; Walter J; Gütschow M
Biochem J; 2010 Aug; 430(1):87-95. PubMed ID: 20518742
[TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma.
Betsunoh H; Mukai S; Akiyama Y; Fukushima T; Minamiguchi N; Hasui Y; Osada Y; Kataoka H
Cancer Sci; 2007 Apr; 98(4):491-8. PubMed ID: 17309599
[TBL] [Abstract][Full Text] [Related]
10. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
11. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2.
Kirchhofer D; Peek M; Lipari MT; Billeci K; Fan B; Moran P
FEBS Lett; 2005 Mar; 579(9):1945-50. PubMed ID: 15792801
[TBL] [Abstract][Full Text] [Related]
12. Conformational lability in serine protease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B.
Shia S; Stamos J; Kirchhofer D; Fan B; Wu J; Corpuz RT; Santell L; Lazarus RA; Eigenbrot C
J Mol Biol; 2005 Mar; 346(5):1335-49. PubMed ID: 15713485
[TBL] [Abstract][Full Text] [Related]
13. Pro-urokinase-type plasminogen activator is a substrate for hepsin.
Moran P; Li W; Fan B; Vij R; Eigenbrot C; Kirchhofer D
J Biol Chem; 2006 Oct; 281(41):30439-46. PubMed ID: 16908524
[TBL] [Abstract][Full Text] [Related]
14. Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells.
Parr C; Jiang WG
Int J Cancer; 2006 Sep; 119(5):1176-83. PubMed ID: 16557597
[TBL] [Abstract][Full Text] [Related]
15. Activation of the zymogen to urokinase-type plasminogen activator is associated with increased interdomain flexibility.
Behrens MA; Botkjaer KA; Goswami S; Oliveira CL; Jensen JK; Schar CR; Declerck PJ; Peterson CB; Andreasen PA; Pedersen JS
J Mol Biol; 2011 Aug; 411(2):417-29. PubMed ID: 21669207
[TBL] [Abstract][Full Text] [Related]
16. Potent and specific inhibition of the biological activity of the type-II transmembrane serine protease matriptase by the cyclic microprotein MCoTI-II.
Gray K; Elghadban S; Thongyoo P; Owen KA; Szabo R; Bugge TH; Tate EW; Leatherbarrow RJ; Ellis V
Thromb Haemost; 2014 Aug; 112(2):402-11. PubMed ID: 24696092
[TBL] [Abstract][Full Text] [Related]
17. Activation of hepatocyte growth factor activator zymogen (pro-HGFA) by human kallikrein 1-related peptidases.
Mukai S; Fukushima T; Naka D; Tanaka H; Osada Y; Kataoka H
FEBS J; 2008 Mar; 275(5):1003-17. PubMed ID: 18221492
[TBL] [Abstract][Full Text] [Related]
18. Membrane-type serine protease-1/matriptase induces interleukin-6 and -8 in endothelial cells by activation of protease-activated receptor-2: potential implications in atherosclerosis.
Seitz I; Hess S; Schulz H; Eckl R; Busch G; Montens HP; Brandl R; Seidl S; Schömig A; Ott I
Arterioscler Thromb Vasc Biol; 2007 Apr; 27(4):769-75. PubMed ID: 17255532
[TBL] [Abstract][Full Text] [Related]
19. Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers.
Herter S; Piper DE; Aaron W; Gabriele T; Cutler G; Cao P; Bhatt AS; Choe Y; Craik CS; Walker N; Meininger D; Hoey T; Austin RJ
Biochem J; 2005 Aug; 390(Pt 1):125-36. PubMed ID: 15839837
[TBL] [Abstract][Full Text] [Related]
20. Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers.
Mukai S; Yamasaki K; Fujii M; Nagai T; Terada N; Kataoka H; Kamoto T
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32290402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
